Kadmon files to sell common stock and warrants
Kadmon announced its intention to offer and sell shares of its common stock and warrants to purchase shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as the lead manager for the offering. Kadmon intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or additional warrants to purchase shares of its common stock, on the same terms and conditions as the shares and warrants offered in the public offering. Kadmon intends to use the net proceeds from the offering for preclinical and clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes.